Collaborative Practice Agreement States

The Federal Pharmacist Operator Status Act, introduced on March 11, 2014 in the U.S. House of Representatives (H.R. 4190), is deferred to the scope of activity of states that can provide and compensate the services of a pharmacist. This legislation has paid greater attention to understanding the variability from one state to another in the field of activity of pharmacists. In this context, the National Alliance of State Pharmacy Associations (NASPA) extended the previous results of the early 2013 research to examine the variability between the provisions of the State Cooperation Agreement. Pharmacists who want to develop a common practice agreement may need help knowing where to start. To support this process, a toolkit entitled “Advancing Team-Based Care through Collaborative Practice Agreements” has been developed. The toolkit is a resource for pharmacists that they can use to develop and implement practical, cooperative agreements to promote team-based care. It offers a customizable template that can be used as a starting point for developing a collaborative practice agreement. In the keynote address at the 2013 APhA Annual Meeting, Reid Blackwelder, president of the American Academy of Family Physicists (AAFP), advocated for a “collaborative vision of health care.” [58] Advanced pharmacy services under a CPA are called collaborative drug therapy management (CDM). [a] While the traditional field of activity of pharmacists provides for the legal power to detect drug-related problems (DRPs) and submit proposals to prescribers (e.g.B. physicians) to resolve DRPs, pharmacists who provide CDMs resolve DRPs directly when they recognize them. This may include prescribing activities that involve selecting and launching drugs to treat a patient`s diagnosed illnesses (as described in the CPA), stopping the use of prescription or non-prescription drugs, changing a patient`s drug treatment (for example.

B change in starch, frequency, route of administration or duration of treatment), evaluation of a patient`s reaction to drug therapy 1999, the Committee on Employment and Research, Research and Employment was set up in 1999. For example, a basal metabolic panel) and the continuation of drug therapy (provision of a new prescription). [7] “We were very fortunate that 20 years ago, when our practical law was last updated, broad terminology was used,” Ziegler said. “This includes designing, implementing, monitoring and managing treatment plans related to patient care, as well as the ability to offer drug treatment management in collaboration with other providers.

Bu yazı yayınlanmıştır Genel . Bookmark permalink.